Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Merrimack Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MACK
Nasdaq
8731
https://www.merrimack.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Merrimack Pharmaceuticals Inc
Merrimack Receives $225 Million Milestone Payment from Ipsen
- Mar 27th, 2024 8:30 pm
Merrimack Reports Full Year 2023 Financial Results
- Mar 7th, 2024 9:30 pm
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company
- Mar 4th, 2024 12:03 pm
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
- Feb 13th, 2024 9:18 pm
We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow
- Dec 10th, 2023 1:20 pm
Merrimack Reports Third Quarter 2023 Financial Results
- Nov 2nd, 2023 8:30 pm
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) most popular amongst retail investors who own 39% of the shares, institutions hold 33%
- Sep 26th, 2023 11:26 am
Merrimack Reports Second Quarter 2023 Financial Results
- Aug 3rd, 2023 8:30 pm
Companies Like Merrimack Pharmaceuticals (NASDAQ:MACK) Can Afford To Invest In Growth
- Jul 3rd, 2023 12:24 pm
Merrimack Reports First Quarter 2023 Financial Results
- May 4th, 2023 9:00 pm
Scroll